Reggie Bowerman saw the doors close at MGI Pharma Inc.’s former headquarters late last year. Now, he’s aiming to open some new doors in biotech for a Canadian startup setting up shop in Minnesota.
News & Media
Pharmatel Fresenius Kabi Pty Ltd, an innovative Australian pharmaceutical company, has chosen the RIVA System (Robotic IV Automation)-a self-contained unit for filling IV syringes and bags- from Intelligent Hospital Systems (IH Systems) to consolidate its
Miraculins Announces Improved Detection of Aggressive Prostate Cancer With Combination of PSP94 and Free Over Total PSA Ratio
Discovery Compliments New Approaches to Prostate Cancer Treatment
Kane Biotech Receives an Additional Contribution from NRC-IRAP to Develop its DispersinB® Antibiofilm Wound Gel Product
Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce that the National Research Council Industrial Research Assistance Program (NRC-IRAP) has inc
Company concludes research on prostate program and seeks licensing partner
Miraculins Inc. (TSX-V:MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, announces today an amendment to the terms of its private placement offering (the "Offering") announced on Novemb
The Life Science Association of Manitoba (LSAM) awarded its annual Life Science Awards this week. Recognizing the leaders and innovators of the life science community, the awards highlight the great work being done in this growing and dynamic industry.
Genesys Venture Inc. (GVI), a life sciences management services firm, is pleased to congratulate DiaMedica Inc. (TSXV:DMA), Kane Biotech Inc. (TSXV:KNE) and Sanomune Inc. on being selected as winners in Canada’s Top 10 Life Sciences Competition, organized
Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and remove microbial biofilms is pleased to announce that DispersinB® Topical Wound Gel has passed the FDA-recommended Cytotoxicity and Primary Skin
Medicure Inc. (TSX: MPH) is pleased to announce initiation of a clinical program to investigate the efficacy and safety of Avastrem(TM) (pyridoxal 5'- phosphate) for the management of tardive dyskinesia. The Company will provide details of the planned tar